Enbrel plant approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Full promotion for Amgen/Wyeth's rheumatoid arthritis agent Enbrel will resume with Dec. 23 approval of Rhode Island manufacturing facility. Amgen estimates that approval of plant will double the overall annual supply of the agent; demand has exceeded supply since 200